Clinical Experience with Purinergic Analgesia 1992 – 2004.

38
Clinical Clinical Experience with Experience with Purinergic Purinergic Analgesia Analgesia 1992 – 200 1992 – 200 4 4

Transcript of Clinical Experience with Purinergic Analgesia 1992 – 2004.

Page 1: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Clinical Experience Clinical Experience

with with

Purinergic AnalgesiaPurinergic Analgesia1992 – 2001992 – 20044

Page 2: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ADENOSINEADENOSINE

• PurinePurine nucleotidenucleotide

• Natural metaboliteNatural metabolite

• Metasympathetic Metasympathetic autonomous mediatorautonomous mediator

• Interacts with Interacts with adenosine (purinergic) adenosine (purinergic) receptorsreceptors А А11, А, А2 2 , А, А33

Page 3: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Adenosine MedicinesAdenosine Medicines

• AdenosineAdenosine ( (purepure nucleosidenucleoside))

• Adenosine MonophosphateAdenosine Monophosphate (АМ (АМPP, , AdenocardAdenocard®®))

• Diadenosine TetraphosphateDiadenosine Tetraphosphate (2А (2АTPTP))

• Sodium AdenosinetriphosphateSodium Adenosinetriphosphate (АТ (АТPP))

• R-phenylisopropyladenosineR-phenylisopropyladenosine (R-PIA(R-PIA))

Page 4: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ATP ATP

Page 5: Clinical Experience with Purinergic Analgesia 1992 – 2004.

АТPАТP

NucleotidaseNucleotidase

ADPADP PhosphatePhosphate

NucleotidaseNucleotidase

АМPАМP PhosphatePhosphate

NucleotidaseNucleotidase

ADENOSINEADENOSINE PhosphatePhosphate

Adenosine Derivatives MetabolismAdenosine Derivatives Metabolism

Page 6: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Adenosine: Main EffectsAdenosine: Main Effects

• VasodilationVasodilation, , especiallyespecially PulmonaryPulmonary

• NegativeNegative chronochrono-, -, dromodromo-, -, batmobatmo- - && inotropicinotropic actionaction

• GI Motility InhibitionGI Motility Inhibition

• Bronchial ConstrictionBronchial Constriction

• Central AnalgesiaCentral Analgesia

• Anti-Inflammatory actionAnti-Inflammatory action

• SedationSedation ? ?????

Page 7: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Influences on InflammationInfluences on Inflammation::

• SuppressesSuppresses free free O-O-radical effluxradical efflux from from

neutrophils (A2)neutrophils (A2)

• DecreasesDecreases TNFTNF-- productionproduction in in

reperfusionreperfusion//reoxygenationreoxygenation

• ReducesReduces IL-6 releaseIL-6 release

• ButBut:: maymay lead to direct histaminelead to direct histamine

releaserelease (А (А33)!)!

Page 8: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ADENOSINEADENOSINE

NucleosidaseNucleosidase

ADENINEADENINE RiboseRibose

AdenindeaminaseAdenindeaminase

HYPOXANTHINEHYPOXANTHINE AmmoniaAmmonia

XanthinoxidaseXanthinoxidase

XANTHINEXANTHINE АmmoniaАmmonia

XanthinoxidaseXanthinoxidase

URIC ACIDURIC ACID

Adenosine CatabolismAdenosine Catabolism

TT1/21/2<10 <10 s!s!

Page 9: Clinical Experience with Purinergic Analgesia 1992 – 2004.

N.B.! N.B.! Any Adenosine drug acts Any Adenosine drug acts only as a direct agonist at only as a direct agonist at

specific cell membrane specific cell membrane receptors, receptors,

butbutdoes not deliver does not deliver

any energy supply!any energy supply!

Page 10: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Adenosine EffectsAdenosine EffectsModulationModulation

+ + POTENTIATIONPOTENTIATION

• DipyridamoleDipyridamole

– – BLOCKINGBLOCKING

• TheophyllineTheophylline

• PentoxiphyllinePentoxiphylline

• CaffeineCaffeine

Page 11: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Adenosine: Routine Clinical UseAdenosine: Routine Clinical Use

• Supraventricular Antiarrhythmic

• Vasodilator, esp. Pulmonary

• Test Bronchoconstrictor

Page 12: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Marta SegerdahlMarta Segerdahl

Alf Sollevi Alf Sollevi

Karolinska Institutet, Karolinska Institutet, StockholmStockholm1992 - 19951992 - 1995

Page 13: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Alf Sollevi:Alf Sollevi:Adenosine infusion during Adenosine infusion during isoflurane-nitrous oxide isoflurane-nitrous oxide anaesthesia: indications of anaesthesia: indications of perioperative analgesic effect // perioperative analgesic effect // AnesthesiaAnesthesia & Analgesia. – & Analgesia. – 1992. – Vol. 80. – P. 595-599.1992. – Vol. 80. – P. 595-599.

Gomaa AA:Gomaa AA:Characteristics of analgesia induced Characteristics of analgesia induced by adenosine triphosphate // by adenosine triphosphate // Pharmacology and Toxicology. – 1987. Pharmacology and Toxicology. – 1987. – V. 61. – P. 199-202.– V. 61. – P. 199-202.

Page 14: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Zarate E, Sa Rego MM, White PF et al.:Zarate E, Sa Rego MM, White PF et al.: Comparison of adenosine and remifentanil Comparison of adenosine and remifentanil infusions as adjuvants to desflurane infusions as adjuvants to desflurane anesthesia // Anesthesiology. – 1999. – anesthesia // Anesthesiology. – 1999. – Vol. 90. – P. 956-963.Vol. 90. – P. 956-963.

Fukunaga AF, Alexander GE, Stark CW:Fukunaga AF, Alexander GE, Stark CW: Characterization of the analgesic actions of Characterization of the analgesic actions of adenosine: comparison of adenosine and adenosine: comparison of adenosine and remifentanil infusions in patients remifentanil infusions in patients undergoing major surgical procedures // undergoing major surgical procedures // Pain. – 2003. – Vol. 101. – P. 129-138.Pain. – 2003. – Vol. 101. – P. 129-138.

Page 15: Clinical Experience with Purinergic Analgesia 1992 – 2004.

AdenosineAdenosine::analgetic per se,analgetic per se,

analgetic adjuvant analgetic adjuvant or or

just direct autonomous just direct autonomous corrector?corrector?

Page 16: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ComparativeComparative Study IStudy I

BBiiiillrrootthh--IIII SSttoommaacchh RReesseeccttiioonn

HHaallootthhaannee uupp ttoo 11%% iinn NN22OO++OO22 ffllooww 22::11

FFeennttaannyyll 00,,0099--00,,4455

mmkkgg··kkgg--11··mmiinn--11

5500%% FFeennttaannyyll ++ 5500%% AAddeennoossiinnee

AAddeennoossiinnee 00,,1177--00,,55

mmkkgg··kkgg--11··mmiinn--11

NN == 1155 NN == 1122 NN == 1122

((FF)) ((FFAA)) ((АА))

Page 17: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Surgery and AnaesthesiaSurgery and AnaesthesiaControl PointsControl Points

1. 1. Starting Point before InductionStarting Point before Induction

2. 2. On Anaesthesia InductionOn Anaesthesia Induction

3. 3. On Skin CuttingOn Skin Cutting

4. 4. During MobilizationDuring Mobilization

5. 5. Restorative Phase (Anastomosis)Restorative Phase (Anastomosis)

6. 6. Recovery from AnaesthesiaRecovery from Anaesthesia

Page 18: Clinical Experience with Purinergic Analgesia 1992 – 2004.

CARDIAC INDEXCARDIAC INDEX

12

34

5

6

Р1

Р2

Р3

0

1

2

3

4

Ряд1

Ряд2

Ряд3

CI

FENTANYL

АDENOSINE

F+А

l / ml / m2 2 · min· min

Page 19: Clinical Experience with Purinergic Analgesia 1992 – 2004.

SVR INDEXSVR INDEX

12

34

5

6

Р1

Р2

Р3

2000

2500

Ряд1

Ряд2

Ряд3

SVRI

FENTANYL

ADENOSINE

F+А

dyn · s · cmdyn · s · cm-5-5 · m · m2 2

Page 20: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Two-component ModelTwo-component Modelof Respiratory of Respiratory

MechanicsMechanics• P – full Circuit PressureP – full Circuit Pressure, , kPkPаа

• R – Airways aerodynamicR – Airways aerodynamic ResistanceResistance, , kPkPаа·s·s//ll

• С - «С - «ThoraxThorax--LungsLungs»» System System ComplianceCompliance, , ll//kPkPаа

P = R·dV/dt + V/C,P = R·dV/dt + V/C,

wherewhere V - VolumeV - Volume, , t - Timet - Time..

Page 21: Clinical Experience with Purinergic Analgesia 1992 – 2004.

AIRWAYS RESISTANCEAIRWAYS RESISTANCE

1

3

5Р1

Р2

Р300,050,10,150,20,250,3

Ряд1

Ряд2

Ряд3

R

FENTANYL

АDENOSINE

F+А

kPkPа·а·ss//ll

Page 22: Clinical Experience with Purinergic Analgesia 1992 – 2004.

THORAXTHORAX & LUNGS COMPLIANCE& LUNGS COMPLIANCE

12

34

56

Р1

Р2

Р30

0,2

0,4

0,6

0,8

1

Ряд1

Ряд2

Ряд3

C

FENTANYL

АDENOSINE

F+А

l/kPаl/kPа

Page 23: Clinical Experience with Purinergic Analgesia 1992 – 2004.

DEAD VOLUME (VDСОDEAD VOLUME (VDСО22 ) )

12

34

5

6Р1

Р2

Р3

0

0,5

1

1,5

2

2,5

Ряд1

Ряд2

Ряд3

VDCO2

FENTANYL

АDENOSINEF+А

ml/kgml/kg

Page 24: Clinical Experience with Purinergic Analgesia 1992 – 2004.

METABOLIC RATEMETABOLIC RATE(Indirect Calorimetry)(Indirect Calorimetry)

12

34

56

Р1

Р2

Р30

100200300400500600700800

Ряд1

Ряд2

Ряд3

MR

FENTANYL

АDENOSINE

F+А

calcal//mm2 2 ··minmin

Page 25: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ComparativeComparative Study IIStudy II

EElleeccttiivvee LLaappaarroossccooppiicc CChhoolleeccyysstteeccttoommyy

IInnhhaallaattiioonn NN22OO++OO22 ffllooww 22::11

FFeennttaannyyll 00,,0099--00,,4455

mmkkgg··kkgg--11··mmiinn--11

AAddeennoossiinnee 00,,1177--00,,55

mmkkgg··kkgg--11··mmiinn--11

NN == 5500 NN == 5500

((FF)) ((АА))

Page 26: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Surgery and AnaesthesiaSurgery and AnaesthesiaControl PointsControl Points

1. 1. Starting Point before InductionStarting Point before Induction

2. 2. On BladderOn Bladder SeparationSeparation

3. 3. Just beforeJust before RecoveryRecovery

Page 27: Clinical Experience with Purinergic Analgesia 1992 – 2004.
Page 28: Clinical Experience with Purinergic Analgesia 1992 – 2004.
Page 29: Clinical Experience with Purinergic Analgesia 1992 – 2004.
Page 30: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Surgery Spectrum Surgery Spectrum

CChhoolleeccyysstteeccttoommyy 112266 GGaassttrreeccttoommyy && ssttoommaacchh rreesseeccttiioonn 3355 EEssoopphhaagguuss rreesseeccttiioonn ((oonnee--ssttaaggeedd)) 11 CCoolloorreeccttaall rreesseeccttiioonnss 1100 AAddrreennaalleeccttoommyy 1199 PPuullmmoonnaarryy rreesseeccttiioonn 11 HHyysstteerreeccttoommyy 1133 TThhyymmeeccttoommyy 55 OOtthheerr ssuurrggeerryy aanndd pprroocceedduurreess 8833 TToottaall 229933

Page 31: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Specific Cases of Specific Cases of Adenosine UseAdenosine Use

• Surgery in Surgery in Myasthenia GravisMyasthenia Gravis – 6 – 6

• Fast Opiate Detoxification under General Fast Opiate Detoxification under General Anaesthesia with Naloxone – 49Anaesthesia with Naloxone – 49

• Anaesthesia in Opiate Addicts – 12Anaesthesia in Opiate Addicts – 12

• Test in Full Consciousness – 1Test in Full Consciousness – 1

Page 32: Clinical Experience with Purinergic Analgesia 1992 – 2004.
Page 33: Clinical Experience with Purinergic Analgesia 1992 – 2004.

Adenosine InfusionAdenosine Infusion

Precision Syringe PumpPrecision Syringe Pump!!!!!!

ECG MonitoringECG Monitoring!!!!!!!!

Official 1% Sodium-ATP solution:

Infusion Rate = 1…5 mg/kg per hour

No Bolus Infusion!

Page 34: Clinical Experience with Purinergic Analgesia 1992 – 2004.

DETAILS &… COMPLICATIONSDETAILS &… COMPLICATIONS

• BradycardiaBradycardia

• BronchospasmBronchospasm

• SSА- А- oror А АVV--block exacerbationblock exacerbation

• SpOSpO2 2 decrease (vasodilation, V/Q decrease (vasodilation, V/Q mismatch)mismatch)

• Hyperuremic metabolic acidosisHyperuremic metabolic acidosis

!!

Page 35: Clinical Experience with Purinergic Analgesia 1992 – 2004.

CONTRAINDICATIONCONTRAINDICATIONSS

• AllAll cases of bronchial obstructioncases of bronchial obstruction

• SSА- А- oror А АVV--conduction conduction disturbancesdisturbances

• Weak sinus syndromeWeak sinus syndrome

• HyperuricemiaHyperuricemia??

Page 36: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ADVANTAGESADVANTAGES• GoodGood AnalgesiaAnalgesia withoutwithout SedationSedation

• Excellent ControllabilityExcellent Controllability

• Stimulates BreathingStimulates Breathing

• Mild Hemodynamic EffectsMild Hemodynamic Effects

• No Postoperative HyperalgesiaNo Postoperative Hyperalgesia

• Treats Pulmonary HypertensionTreats Pulmonary Hypertension

• May be used in Opiate AddictsMay be used in Opiate Addicts

• No Law RestrictionsNo Law Restrictions

Page 37: Clinical Experience with Purinergic Analgesia 1992 – 2004.

ANALGESIC SPECTRUM:ANALGESIC SPECTRUM:BETWEEN HYSTORY & BETWEEN HYSTORY &

FUTURE…FUTURE…

• OPIATESOPIATES

22-ADRENOPOSITIVE AGENTS-ADRENOPOSITIVE AGENTS

• PURINE DERIVATIVESPURINE DERIVATIVES

• SEROTONINE (5-HT) AGONISTSSEROTONINE (5-HT) AGONISTS

Page 38: Clinical Experience with Purinergic Analgesia 1992 – 2004.

FUTURE ANALGESIC FUTURE ANALGESIC SETSET

• PREEMPTIVE (ANTI-INFLAMMATORY) PREEMPTIVE (ANTI-INFLAMMATORY) ANALGESICS:ANALGESICS: NSAIDs, PROTEINASE INHIBITORS, NSAIDs, PROTEINASE INHIBITORS, GLUCOCORTICOIDSGLUCOCORTICOIDS

• INTRAOPERATIVE ANALGESICS – DIRECT INTRAOPERATIVE ANALGESICS – DIRECT AUTONOMOUS CORRECTORS: AUTONOMOUS CORRECTORS: 22--ADRENOPOSITIVE AGENTS, PURINE DERIVATIVES, ADRENOPOSITIVE AGENTS, PURINE DERIVATIVES, -BLOCKERS, Ca-BLOCKERS, Ca++++-CHANNEL BLOCKERS, etc.-CHANNEL BLOCKERS, etc.

• ““FULL-CONSCIOUSNESS” ANALGESICS:FULL-CONSCIOUSNESS” ANALGESICS: OPIATES, OPIATES, NMDA-ANTAGONISTSNMDA-ANTAGONISTS